NRx Pharmaceuticals, Inc. (NRXP)
NASDAQ: NRXP · Real-Time Price · USD
2.710
+0.120 (4.63%)
Oct 15, 2026, 4:00 PM EDT - Market closed
NRx Pharmaceuticals Revenue
NRx Pharmaceuticals had revenue of $1.10M in the quarter ending June 30, 2026. This brings the company's revenue in the last twelve months to $3.39M. In the year 2025, NRx Pharmaceuticals had annual revenue of $1.23M. That makes NRx Pharmaceuticals the 41,089th largest company in the world by revenue and 5,522nd in the United States.
Revenue (ttm)
$3.39M
Revenue Growth
n/a
P/S Ratio
34.54
Revenue / Employee
$117,034
Employees
29
Market Cap
117.24M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 1.23M | - | - |
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Foghorn Therapeutics | 36.74M |
| LENZ Therapeutics | 21.48M |
| Seer, Inc. | 14.22M |
| Armata Pharmaceuticals | 5.54M |
| Humacyte | 2.12M |
| Spruce Biosciences | 697.00K |
| Outlook Therapeutics | -1.16M |
NRXP News
- 14 hours ago - Psychedelic: NRx Pharmaceuticals receives FDA labeling review letter - TheFly
- 16 hours ago - NRx receives FDA review letter for Ketamine product requesting minor changes - TheFly
- 16 hours ago - NRx Pharmaceuticals Announces Receipt of FDA Labeling Review Letter for Preservative-Free Ketamine - GlobeNewsWire
- 15 days ago - NRx Pharmaceuticals awarded initial $11.18M DARPA prime contract - TheFly
- 15 days ago - NRx Defense Systems, an NRx Company (Nasdaq:NRXP) Awarded $11 Million Dollar DARPA Prime Contract to Evaluate Robotic Magnetic Stimulation in conjunction with NRX-101 for Treatment of Resistant Depression - GlobeNewsWire
- 4 weeks ago - NRx Pharmaceuticals says FDA reclassifies ANDA amendment to ‘minor’ - TheFly
- 4 weeks ago - NRx Pharmaceuticals (Nasdaq: NRXP) Reports Update from the FDA Revising Previous Major Amendment to a Minor Amendment for Preservative-free Ketamine - GlobeNewsWire
- 4 weeks ago - GeNeuro, Inc., an NRx Company (Nasdaq:NRXP) is awarded European Patent Rights for GNK-301, a novel drug candidate to treat Amyotrophic Lateral Sclerosis (ALS) - GlobeNewsWire